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ABSTRACT
In contrast to the adult, the third-trimester foetus experiences one of the most intense peri-
ods of growth and maturation of its lifetime. Early development is characterized by the exis-
tence of critical periods when environmental factors effectively produce long-lasting
changes.
Proliferative retinopathy of prematurity (ROP) is a potentially blinding disease character-
ized by uncontrolled retinal angiogenesis. This pathologic angiogenesis is the target for two
new treatment modalities for ROP, i.e. intravitreal anti-VEGF (bevacizumab) and systemic
propranolol, which are being evaluated in ongoing or planned studies. VEGF is essential for
normal angiogenesis in a growing infant, and the adrenergic system is important for many
organ systems and, in addition, for plasticity of the visual and olfactory systems.
Conclusion: This viewpoint raises concerns regarding the currently studied antian-
giogenetic treatments for ROP and their possible general effects on the developing preterm
infant.
In contrast to the adult, the third-trimester foetus experi-
ences one of the most intense periods of growth and matu-
ration of its lifetime. Early development is characterized by
the existence of critical periods when environmental factors
effectively produce long-lasting changes. An example is that
of the antiangiogenetic substance thalidomide, which dur-
ing a very limited time period in early pregnancy causes
gross malformations. Angiogenesis is important for the alve-
olarization of the lungs, which in humans mainly takes
place after birth in infants born at term (1), and in newborn
and infant rats, thalidomide (2) as well as a VEGF-receptor
inhibitor (3) reduced lung vascular density and alveolariza-
tion. In the central nervous system, maturational processes
occur at different times in different brain regions and neural
circuits, and therefore, critical periods may be speciﬁc for
each brain region or neurotransmitter system (4).
The very preterm infant has lost nutrients and other fac-
tors supplied by the mother and is exposed to poor nutrition,
hyperoxia⁄hypoxia, infections and other stresses resulting in
impaired growth and development. In the eye, reduced
physiologic angiogenesis may lead to hypoxia followed by
uncontrolled vessel growth. This pathologic angiogenesis is
the target for two new treatment modalities for retinopathy
of prematurity (ROP), which are being evaluated in ongoing
or planned studies. We would like to express our concern
about possible adverse effects of these medications on the
development of these vulnerable infants.
In the Pan-VEGF Blockade for the Treatment of Retino-
pathy of Prematurity (BLOCK-ROP) study (ClinicalTrials.
gov Identiﬁer: NCT01232777), intravitreal injection of
0.625 or 0.75 bevacizumab (Avastin
 ), an anti-VEGF anti-
body, will be compared with standard of care laser for type
1 prethreshold ROP diagnosed at 30–36 postmenstrual
weeks. In the Safety and Efﬁcacy of propranolol in new-
borns with retinopathy of prematurity (PROP-ROP) study
(ClinicalTrials.gov Identiﬁer: NCT01079715) (5), preterm
infants with stage 2 ROP in zone II or III without plus-
disease will receive systemic propranolol, a nonselective
beta blocker, up to 90 days in addition to standard care in
comparison with standard treatment only.
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VEGF promotes both normal and pathologic angiogenesis,
and it is a neuronal survival factor. The blockage of VEGF
with Avastin
  may thus inﬂuence other processes than
pathologic angiogenesis in the eye. Bevacizumab is a large
molecule, and an advantage put forward is its inability to
escape the eye unless in very small amounts (6). However,
one intravitreal injection of 1.25 mg⁄50 lL in three adult
cynomolgus macaques weighing 3.9–5.5 kg resulted in a
maximum serum concentration of 1430 ± 186 ng⁄mL
1 week after injection and concentration declined more
slowly than in the eye, with little change after 4 weeks, and
was 67 ± 24.3 ng⁄mL after 8 weeks (7).
In a recent study (BEAT-ROP, ClinicalTrials.gov Identi-
ﬁer: NCT01232777) (n = 150), infants with stage 3+ ROP
were given bilateral intravitreal injections of 0.625 mg of
Avastin
  bilaterally (6) resulting in a dose equal to that
given to the adult macaques. As the blood retinal barrier
is compromised in eyes with pathologic neovasculariza-
tion, one may fear higher serum concentrations in these
infants than in the monkeys. Regarding safety, the authors
of this study concluded that 2800 infants were needed to
assess mortality and an even larger sample for local or sys-
temic toxicity and that the study was too small to address
the question of whether intravitreal bevacizumab is safe.
Thus, no attempts to monitor adverse effects were made,
and serum concentrations of bevacizumab were not
reported.
PROPRANOLOL FOR ROP
Propranolol has been found to be efﬁcient in reducing the
growth of infantile hemangiomas in a number of patients
(8,9), although no controlled trials of safety and efﬁcacy
have been reported yet. In a mouse model of ROP, propran-
olol was protective against retinal angiogenesis and amelio-
rated blood–retina barrier dysfunction in oxygen-induced
retinopathy (OIR) (10).
The hypothesis of the PROP-ROP study is that in preterm
infants with ROP, VEGF overexpression could be induced
by beta2-adrenoreceptor stimulation and that propranolol,
administered when ROP stage 2 is detected in zone II or III,
could reduce the progression of the disease. As mentioned
by the authors, most cases of ROP stage 2 regress spontane-
ously, which means that most of the infants treated with
propranolol never risked blindness anyway.
Propranolol is reported to be well tolerated in most cases.
However, hemodynamic effects such as bradycardia and
hypotension as well as metabolic effects such as hypoglyce-
mia may be serious (11–13). In addition, beta blockers may
cause masking of hypoglycemia, insulin resistance and dysl-
ipidemia (14). It is well known that very preterm infants
already have an increased risk of hypotension (15) and
deranged glucose metabolism including insulin resistance
(16).
Less is known about the roles of the adrenergic system
and the beta-adrenergic receptors on the development of
the premature infant’s brain. In rats, OIR is induced by
exposure to increased oxygen concentrations from birth to
postnatal day 11 followed by room air for 7 days after which
proliferative retinopathy, similar to human stage 3 ROP, is
found (17). In the rat brain, the timing of noradrenergic cor-
tical innervations coincides with neurogenesis, neuronal
migration, sprouting of cellular processes and the formation
of synaptic contacts and occurs mainly during the ﬁrst
3 weeks of postnatal life (18), just like the development of
OIR and the transition to proliferative disease. Noradrena-
lin is a neurotransmitter that is essential for the modulation
of memory (19) and for the plasticity of visual (20,21) and
olfactory systems (19). Propranolol passes the blood–brain
barrier and causes memory loss in chicks (19) and blocks
early olfactory learning in rats (22).
It is likely that during the period when pathologic angio-
genesis is a threat to the eye, windows of susceptibility occur
in other parts of the central nervous system, where adequate
angiogenesis and development of neural and other tissues
are essential for later normal function. Administering potent
blockers of VEGF and of the adrenergic system during these
periods may be deleterious. As long as we lack methods to
explore how the growth and modulation of neuronal net-
works are orchestrated, medications that possibly alter
these processes for the rest of life should be avoided. In pre-
term infants prone to abnormal brain development, it will
be impossible to sort out adverse effects of these drugs.
Laser ablation of the retina is not ideal, but its effects are
restricted to the eye and it usually works well. Antiangio-
genetic treatment might be indicated in serious cases when
laser treatment has failed, but that is different from it being
an alternative to laser. There might be a place for proprano-
lol for pathologic vessels just like for severe hemangiomas,
but its use as prophylaxis to prevent proliferative ROP
during stage 2 like in the PROP-ROP study should be ques-
tioned. If Avastin
  is further used in infants, monitoring of
serum bevacizumab and exploration of its pharmacokinet-
ics and effects on premature babies are needed.
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